Multimodality treatment for esophageal cancer - Surgery, is it necessary?

食管癌综合治疗——手术，有必要吗？

• 批准号: 15591459
• 负责人: FUJITA Hiromasa
• 金额: $ 2.24万
• 依托单位: Kurume University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2003
• 资助国家: 日本
• 起止时间: 2003 至 2006
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/en/grant/KAKENHI-PROJECT-15591459/
• 关键词: Cancer in the thoracic esophagus; Multimodality treatment; Esophagectomy; Definitive chemoradiotherapy; Neoadjuvant therapy; Potentially-resectable cancer; Cancer at the intermediate stage; Informed consent; Neoadluvant療法; 修学治療; 根治的放射線化学療法

Purpose : To compare the outcomes after esophagectomy versus those after chemoradiotherapy for potentially respectable (T2-3,NO-1,MO) esophageal cancerMaterials:1) squamous cell carcinoma in the thoracic esophagus2) potentially respectable cancer, cT2-3, cNO-1, cMO, cStage II-III3) patients at a low risk for both esophagectomy and definitive chemoradiotherapy4) no double primary cancers5) obtaining informed consentMethods : Patients choose one arm among the following three treatment arms after informed consent.1) esophagectomy (S)2) definitive chemoradiotherapy (CRT)3) neoadjuvant chemoradiotherapy (NA) ; Patients choose surgery or non-surgical treatment after being informing of the response to the neoadjuvant chemoradiotherapyResults : A hundred and two patients participated in this trial, from 2003 to 2006. There were 76 patients in the esophagectomy (S) group, 18 in the definitive chemoradiotherapy (CRT) group, and 8 in the neoadjuvant chemoradiotherapy (NA) group.1) S Group : There … More were 59 patients who underwent Ro resection, 16 who underwent R1R2 resection, and one who underwent only exploratory thoracotomy. The 1-, 2-, and 3-year-survival rate was 81%, 56%, and 49%, respectively in the S Group.2) CRT Group : There were 14 patients with complete response, and 4 with incomplete response. There was no patient who underwent salvage surgery. The 1-, 2-, and 3-year-survival rate was 89%, 68%, and 46%, respectively in the CRT Group.3) NA Group : There were three patients who underwent esophagectomy, and five who did not. The 1-, and 2-year-survival rate was 50% and 50%, respectively in the NA Group.The 1-, 2-, and 3-year-survival rate was 81%, 56%, and 49%, respectively in those patients who chose the surgical treatment at first, and was 74%, 60%, and 40%, respectively in those patients who chose the non-surgical treatment at first (the CRT Group + the NA Group)Conclusions : The outcomes after chemoradiotherapy for potentially respectable (T2-3,NO-1,MO) esophageal cancer may be similar to those after surgery. Less

材料：1)胸段食道鳞状细胞癌2)潜在可切除癌CT2-3，CNO-1，CMO，cStage II-III3)低风险患者同时接受食道切除和明确的放化疗4)无双原发癌5)获得知情同意方法：患者在知情同意后从以下三种治疗方案中选择一种：1)食道切除术(S)2)明确的放化疗(CRT)3)新辅助放化疗(NA)；患者在被告知新辅助放化疗的疗效后选择手术或非手术治疗。结果：2003年至2006年有102名患者参加了这项试验。食道切除术(S)组76例，明确放化疗组18例，新辅助放化疗(NA)组8例。1)S组：There…更多的患者接受了Ro切除，16例接受了R1R2切除，1例仅接受了探查开胸手术。S组1、2、3年生存率分别为81%、56%、49%。2)放疗组完全缓解14例，不完全缓解4例。无一例患者接受抢救手术。CRT组的1、2、3年生存率分别为89%、68%和46%。3)NA组：有3例患者接受了食道切除术，5例没有接受手术。先选择手术治疗的1、2、3年生存率分别为81%、56%、49%，先选择非手术治疗(CRT组+NA组)的1、2、3年生存率分别为74%、60%、40%。结论：T2-3、NO-1、MO食道癌放化疗后的预后可能与手术后相似。较少

项目成果

Surgery of cancer in the cervical esophagus

颈段食管癌手术

• 发表时间: 2006
• 期刊: Syuzyutu (Surgery) 60(6)
• 作者: H Fujita;N Mori
• 通讯作者: N Mori

治療方法の進歩による下咽頭癌治療成績の向上

通过治疗方法的进步改善下咽癌的治疗效果

• 发表时间: 2006
• 期刊: 日本気管食道科学会会報 57巻・4号
• 作者: 梅野博仁;千々和秀記;藤田博正ほか
• 通讯作者: 藤田博正ほか

Dissection of the lymph nodes along the thoracic aorta in esophageal cancer surgery

食管癌手术中胸主动脉淋巴结清扫

• 发表时间: 2004
• 期刊: Syuzyutu (Surgery) 58(1)
• 作者: H Fujita;S Sueyoshi;T Tanaka;et al.
• 通讯作者: et al.

[Chemoradiotherapy for esophageal cancer].

• 发表时间: 2003-07
• 期刊: Gan to kagaku ryoho. Cancer & chemotherapy
• 作者: H. Fujita;S. Sueyoshi;Toshiaki Tanaka;H. Sasahara;S. Matono;H. Yamana;K. Shirouzu;G. Suzuki;N. Hayabuchi

Surgical procedure for cancer in the cervical esophagus

颈段食管癌的手术治疗

• 发表时间: 2006
• 期刊: Rinsyo syuyou practice (The Practice of Medical Oncology) 2(3)
• 作者: H Fujita;N Mori;H Chijiwa
• 通讯作者: H Chijiwa